Our findings provided proof of the BRCA 1.0 POC Research Assay’s analytical performance, while the clinical utility was evidenced by reaching the 10% threshold for cost-effective variant detection in patients with hormone receptor-positive BC, not currently considered for routine BRCA1/2 testing in SA. This evidence concerns the gene NR4A1 and breast cancer.